Brian Goff serves as the Chief Executive Officer at Agios Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative therapies for genetically defined diseases. With a robust background in the life sciences industry, Goff has been instrumental in steering Agios towards its mission of improving patients' lives through targeted treatments. He joined Agios in 2014 as the Chief Operating Officer and ascended to the CEO position in 2017, bringing with him a wealth of experience from previous roles at major pharmaceutical companies. Prior to joining Agios, Goff held significant leadership positions that honed his strategic and operational expertise. He spent over a decade at Genentech, where he served as Senior Vice President of Global Product Strategy, playing a key role in the successful launch and commercialization of multiple blockbuster oncology drugs. Before Genentech, Goff worked at Amgen, where he contributed to the development and marketing of several important biologic therapies. His extensive experience in both the operational and strategic aspects of drug development has been pivotal in guiding Agios through the complex landscape of pharmaceutical innovation. As CEO of Agios, Goff is responsible for overseeing the company's overall strategy, operations, and growth. Under his leadership, Agios has made significant strides in advancing its pipeline of novel therapies, particularly in the fields of oncology and rare genetic diseases. One of his notable achievements includes the successful launch of TIBSOVO®, a first-in-class treatment for acute myeloid leukemia (AML) with an IDH1 mutation. Goff's vision and leadership continue to drive Agios forward, fostering a culture of innovation and patient-centricity that positions the company as a leader in precision medicine.